The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT03778957




Registration number
NCT03778957
Ethics application status
Date submitted
28/11/2018
Date registered
18/12/2018
Date last updated
1/08/2019

Titles & IDs
Public title
A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma
Scientific title
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination With Either Durvalumab Monotherapy or Durvalumab Plus Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma
Secondary ID [1] 0 0
2018-002134-20
Secondary ID [2] 0 0
D933GC00001
Universal Trial Number (UTN)
Trial acronym
EMERALD-1
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hepatocellular Carcinoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Non melanoma skin cancer
Cancer 0 0 0 0
Kidney
Cancer 0 0 0 0
Liver

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Durvalumab
Treatment: Drugs - Bevacizumab
Other interventions - Placebo
Treatment: Surgery - Transarterial Chemoembolization (TACE)

Experimental: Arm A - Transarterial Chemoembolization (TACE) in combination with Durvalumab

Experimental: Arm B - Transarterial Chemoembolization (TACE) in combination with Durvalumab and Bevacizumab

Placebo Comparator: Arm C - Transarterial Chemoembolization (TACE) in combination with Placebos


Treatment: Drugs: Durvalumab
Durvalumab IV (intravenous)

Treatment: Drugs: Bevacizumab
Bevacizumab IV (intravenous)

Other interventions: Placebo
Saline solution for Durvalumab and/or Bevacizumab masking (IV intravenous)

Treatment: Surgery: Transarterial Chemoembolization (TACE)
TACE (chemo and embolic agent injection into the hepatic artery)

Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Intervention code [3] 0 0
Treatment: Surgery
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression Free Survival (PFS) for Arm A vs Arm C - PFS per Blinded Independent Central Review (BICR) assessment will be defined as the time from the date of randomization until the date of first objective disease progression or death
Timepoint [1] 0 0
Approximately 5 years
Secondary outcome [1] 0 0
Progression Free Survival (PFS) for Arm B vs Arm C - PFS per Blinded Independent Central Review (BICR) assessment will be defined as the time from the date of randomization until the date of first objective disease progression or death
Timepoint [1] 0 0
Approximately 5 years
Secondary outcome [2] 0 0
Overall Survival (OS) - OS is defined as the time from the date of randomization until death due to any cause
Timepoint [2] 0 0
Approximately 5 years
Secondary outcome [3] 0 0
Health status/quality of life measured by European Organization for Research and Treatment of Cancer (EORTC) 30-item core quality of life questionnaire (QLQ-30) - Collection of patient reported outcome (PRO) measures to assess time to deterioration in global health status/quality of life (QoL), functioning (physical) and symptoms
Timepoint [3] 0 0
Approximately 5 years
Secondary outcome [4] 0 0
Disease-related symptoms measured by European Organization for Research and Treatment of Cancer (EORTC) 18-item hepatocellular cancer health-related quality of life questionnaire (QLQ-HCC18) - Collection of patient reported outcome (PRO) measures to assess time to deterioration in symptoms
Timepoint [4] 0 0
Approximately 5 years

Eligibility
Key inclusion criteria
Key

- No evidence of extrahepatic disease on baseline imaging

- Disease not amenable to curative surgery or transplantation or curative ablation but
disease amenable to TACE

- Child-Pugh score class A to B7 and Eastern Cooperative Oncology Group (ECOG)
performance status of 0 or 1 at enrollment

- Measurable disease by Modified Response Criteria in Solid Tumors (mRECIST) criteria

- Adequate organ and marrow function

Key
Minimum age
18 Years
Maximum age
110 Years
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion Criteria

- Any history of nephrotic or nephritic syndrome

- Clinically significant cardiovascular disease or history of arterioembolic event
including a stroke or myocardial infarction

- Any prior or current evidence of coagulopathy or bleeding diathesis or patients who
had any kind of surgery in the past 28 days

- History of abdominal fistula or GI perforation, non healed gastric ulcer that is
refractory to treatment, or active GI bleeding within 6 months prior to enrollment

- Patients with Vp3 and Vp4 portal vein thrombosis on baseline imaging are excluded

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Research Site - Benowa
Recruitment hospital [2] 0 0
Research Site - Box Hill
Recruitment hospital [3] 0 0
Research Site - Camperdown
Recruitment hospital [4] 0 0
Research Site - Clayton
Recruitment hospital [5] 0 0
Research Site - Herston
Recruitment hospital [6] 0 0
Research Site - Liverpool
Recruitment hospital [7] 0 0
Research Site - Prahan
Recruitment postcode(s) [1] 0 0
4217 - Benowa
Recruitment postcode(s) [2] 0 0
3128 - Box Hill
Recruitment postcode(s) [3] 0 0
2050 - Camperdown
Recruitment postcode(s) [4] 0 0
3168 - Clayton
Recruitment postcode(s) [5] 0 0
4029 - Herston
Recruitment postcode(s) [6] 0 0
2170 - Liverpool
Recruitment postcode(s) [7] 0 0
3004 - Prahan
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
District of Columbia
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Hawaii
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Louisiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Michigan
Country [11] 0 0
United States of America
State/province [11] 0 0
Minnesota
Country [12] 0 0
United States of America
State/province [12] 0 0
Missouri
Country [13] 0 0
United States of America
State/province [13] 0 0
Nebraska
Country [14] 0 0
United States of America
State/province [14] 0 0
New York
Country [15] 0 0
United States of America
State/province [15] 0 0
North Carolina
Country [16] 0 0
United States of America
State/province [16] 0 0
Oregon
Country [17] 0 0
United States of America
State/province [17] 0 0
Pennsylvania
Country [18] 0 0
United States of America
State/province [18] 0 0
South Dakota
Country [19] 0 0
United States of America
State/province [19] 0 0
Texas
Country [20] 0 0
Brazil
State/province [20] 0 0
Barretos
Country [21] 0 0
Brazil
State/province [21] 0 0
Florianópolis
Country [22] 0 0
Brazil
State/province [22] 0 0
Porto Alegre
Country [23] 0 0
Brazil
State/province [23] 0 0
Rio de Janeiro
Country [24] 0 0
Brazil
State/province [24] 0 0
Sao Paulo
Country [25] 0 0
Brazil
State/province [25] 0 0
São José do Rio Preto
Country [26] 0 0
Canada
State/province [26] 0 0
Ontario
Country [27] 0 0
Canada
State/province [27] 0 0
Quebec
Country [28] 0 0
China
State/province [28] 0 0
Beijing
Country [29] 0 0
China
State/province [29] 0 0
Changchun
Country [30] 0 0
China
State/province [30] 0 0
Changsha
Country [31] 0 0
China
State/province [31] 0 0
Chengdu
Country [32] 0 0
China
State/province [32] 0 0
Guangzhou
Country [33] 0 0
China
State/province [33] 0 0
Hangzhou
Country [34] 0 0
China
State/province [34] 0 0
Nanjing
Country [35] 0 0
China
State/province [35] 0 0
Shanghai
Country [36] 0 0
China
State/province [36] 0 0
Shenyang
Country [37] 0 0
China
State/province [37] 0 0
Zhengzhou
Country [38] 0 0
China
State/province [38] 0 0
Zhuhai
Country [39] 0 0
France
State/province [39] 0 0
Bondy
Country [40] 0 0
France
State/province [40] 0 0
Clichy
Country [41] 0 0
France
State/province [41] 0 0
Grenoble cedex 9
Country [42] 0 0
France
State/province [42] 0 0
Lyon Cedex 04
Country [43] 0 0
France
State/province [43] 0 0
Montpellier CEDEX 5
Country [44] 0 0
France
State/province [44] 0 0
Nice Cedex 3
Country [45] 0 0
France
State/province [45] 0 0
Pessac
Country [46] 0 0
France
State/province [46] 0 0
Toulouse Cedex 9
Country [47] 0 0
France
State/province [47] 0 0
Vandoeuvre Les Nancy
Country [48] 0 0
Hong Kong
State/province [48] 0 0
Shatin
Country [49] 0 0
India
State/province [49] 0 0
Bangalore
Country [50] 0 0
India
State/province [50] 0 0
Chennai
Country [51] 0 0
India
State/province [51] 0 0
Hyderabad
Country [52] 0 0
India
State/province [52] 0 0
Kolkata
Country [53] 0 0
India
State/province [53] 0 0
Madurai
Country [54] 0 0
India
State/province [54] 0 0
Mumbai
Country [55] 0 0
India
State/province [55] 0 0
Nasik
Country [56] 0 0
India
State/province [56] 0 0
New Delhi
Country [57] 0 0
India
State/province [57] 0 0
Pune
Country [58] 0 0
India
State/province [58] 0 0
Surat
Country [59] 0 0
India
State/province [59] 0 0
Vijayawada
Country [60] 0 0
India
State/province [60] 0 0
Vishakhapatnam
Country [61] 0 0
Italy
State/province [61] 0 0
Arezzo
Country [62] 0 0
Italy
State/province [62] 0 0
Milano
Country [63] 0 0
Italy
State/province [63] 0 0
Padova
Country [64] 0 0
Italy
State/province [64] 0 0
Pisa
Country [65] 0 0
Japan
State/province [65] 0 0
Bunkyo-ku
Country [66] 0 0
Japan
State/province [66] 0 0
Chiba-shi
Country [67] 0 0
Japan
State/province [67] 0 0
Chuo-ku
Country [68] 0 0
Japan
State/province [68] 0 0
Fukuoka-shi
Country [69] 0 0
Japan
State/province [69] 0 0
Hiroshima-shi
Country [70] 0 0
Japan
State/province [70] 0 0
Kurume-shi
Country [71] 0 0
Japan
State/province [71] 0 0
Morioka-shi
Country [72] 0 0
Japan
State/province [72] 0 0
Musashino-shi
Country [73] 0 0
Japan
State/province [73] 0 0
Nagoya-shi
Country [74] 0 0
Japan
State/province [74] 0 0
Okayama
Country [75] 0 0
Japan
State/province [75] 0 0
Osaka-shi
Country [76] 0 0
Japan
State/province [76] 0 0
Osakasayama-shi
Country [77] 0 0
Japan
State/province [77] 0 0
Sapporo-shi
Country [78] 0 0
Japan
State/province [78] 0 0
Tsu-shi
Country [79] 0 0
Japan
State/province [79] 0 0
Yokohama-shi
Country [80] 0 0
Korea, Republic of
State/province [80] 0 0
Busan
Country [81] 0 0
Korea, Republic of
State/province [81] 0 0
Daegu
Country [82] 0 0
Korea, Republic of
State/province [82] 0 0
Goyang-si
Country [83] 0 0
Korea, Republic of
State/province [83] 0 0
Seoul
Country [84] 0 0
Mexico
State/province [84] 0 0
Alc. Cuauhtémoc
Country [85] 0 0
Mexico
State/province [85] 0 0
Culiacan
Country [86] 0 0
Mexico
State/province [86] 0 0
Guadalajara
Country [87] 0 0
Mexico
State/province [87] 0 0
Mexico, Distrito Federal+52 55
Country [88] 0 0
Mexico
State/province [88] 0 0
Mexico
Country [89] 0 0
Mexico
State/province [89] 0 0
Monterrey
Country [90] 0 0
Mexico
State/province [90] 0 0
Mérida
Country [91] 0 0
Mexico
State/province [91] 0 0
Tuxtla Gutierrez
Country [92] 0 0
Spain
State/province [92] 0 0
Córdoba
Country [93] 0 0
Spain
State/province [93] 0 0
Pamplona
Country [94] 0 0
Spain
State/province [94] 0 0
San Sebastián(Guipuzcoa)
Country [95] 0 0
Taiwan
State/province [95] 0 0
Kaohsiung
Country [96] 0 0
Taiwan
State/province [96] 0 0
Taichung
Country [97] 0 0
Taiwan
State/province [97] 0 0
Tainan
Country [98] 0 0
Taiwan
State/province [98] 0 0
Taipei
Country [99] 0 0
Taiwan
State/province [99] 0 0
Tao Yuan
Country [100] 0 0
Thailand
State/province [100] 0 0
Bangkok
Country [101] 0 0
Thailand
State/province [101] 0 0
Chiang Mai
Country [102] 0 0
Thailand
State/province [102] 0 0
Khon Kaen
Country [103] 0 0
Thailand
State/province [103] 0 0
Songkla
Country [104] 0 0
Vietnam
State/province [104] 0 0
Hanoi City
Country [105] 0 0
Vietnam
State/province [105] 0 0
Hanoi
Country [106] 0 0
Vietnam
State/province [106] 0 0
Ho Chi Minh City
Country [107] 0 0
Vietnam
State/province [107] 0 0
Ho Chi Minh

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
AstraZeneca
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
A global study to evaluate transarterial chemoembolization (TACE) in combination with
durvalumab and bevacizumab therapy in patients with locoregional hepatocellular carcinoma
Trial website
https://clinicaltrials.gov/show/NCT03778957
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Bruno Sangro, MD
Address 0 0
Clinica Universidad de Navarra
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
AstraZeneca Clinical Study Information Center
Address 0 0
Country 0 0
Phone 0 0
1-877-240-9479
Fax 0 0
Email 0 0
information.center@astrazeneca.com
Contact person for scientific queries

Summary results
For IPD and results data, please see https://clinicaltrials.gov/show/NCT03778957